BridgeMD
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic head and neck cancer patients
EU CTIS ID: 2024-514919-10-00
What this study is testing
To investigate if the use of weekly low dose cisplatin increases compliance to the planned chemotherapy scheme in LA-HNSCC patients with low SMM to a level of compliance to three-weekly high dose cisplatin of patients without low SMM.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - considered, eligible and planned for primary cisplatin CRT by treating physician; - eighteen years of age or older; - sufficient understanding of Dutch and medical consequences to give informed consent.
You likely can't join if
- - mentally disabled or patients with significantly altered mental status that would prohibit understanding and giving informed consent; - a history of bilateral lymph node dissection in the neck and no available (PET-)CT scan of the third lumbar vertebra; - an absolute contraindication for cisplatin as defined by the treating physician, including relevant pre-existing kidney insufficiency, clinically apparent vascular disease (for example claudicatio intermittens), clinically relevant perceptive deafness, serious neuropathy and poor performance score;
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.